scholarly journals Predictive value of pancreatic dose-volume metrics on sarcopenia rate in gastric cancer patients treated with adjuvant chemoradiotherapy

2019 ◽  
Vol 38 (4) ◽  
pp. 1713-1720 ◽  
Author(s):  
Yi Li ◽  
Wen-bo Wang ◽  
Huan-gang Jiang ◽  
Jing Dai ◽  
Ling Xia ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Value ◽  
Adjuvant Chemoradiotherapy ◽  
Dose Volume ◽  
Gastric Cancer Patients

scholarly journals D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy

2016 ◽  
Vol 5 (10) ◽  
pp. 2773-2780 ◽  
Author(s):  
Jin Peng ◽  
Yuehua Wei ◽  
Fuxiang Zhou ◽  
Jing Dai ◽  
Yahua Zhong ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Adjuvant Chemoradiotherapy ◽  
Stage Iiic ◽  
Resected Stage ◽  
Gastric Cancer Patients

Neutrophil-to-lymphocyte ratio (NLR) to predict the short-term and long-term outcomes of gastric cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15560-e15560
Author(s):  
Ryoichi Miyamoto ◽  
Satoshi Inagawa ◽  
Naoki Sano ◽  
Sosuke Tadano ◽  
Masayoshi Yamamoto
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Value ◽  
Disease Free Survival ◽  
Perioperative Outcomes ◽  
Survival Times ◽  
Long Term Outcomes ◽  
Short Term ◽  
Gastric Cancer Patients

e15560 Background: Preoperative NLR was well known as highly repeatable, cost-effective and widely available long-term postoperative prognostic marker of gastric cancer patients. However, the utility of preoperative NLR to predict short-term outcomes in gastric cancer patients remains unclear. In this study, we addressed whether the preoperative NLR is a predictive value of short-term outcome in gastric cancer patients. Methods: We retrospectively evaluated 154 consecutive gastric cancer patients. Mean NLR was calculated, and 3.5 was set as cut-off value. The patient characteristics and perioperative outcomes were respectively compared. In addition, median survival times (MSTs) were also compared. In terms of stage II/III (UICC 7th) gastric cancer patients, median disease-free survival times (MDFSTs) were compared between the two groups. Results: The patients were then divided into two groups: low-NLR group (n = 110) and high-NLR group (n = 44). Among low-NLR group and high-NLR group, significant differences were respectively observed in preoperative symptoms [56 (51%) vs. 31 (70%); p = 0.027] and perioperative outcomes including postoperative complications [3 (2.7%) vs. 5 (11.3%); p = 0.015], intraoperative blood loss (158 ± 168 g vs. 232 ± 433 g; p = 0.022), and intraoperative blood transfusion [0 vs. 3 (6.8%); p = 0.042]. MSTs and MDFSTs were significantly differed (812 vs. 594 days; p = 0.04, 848 vs. 475 days; p = 0.03, respectively). Conclusions: The present study indicated that preoperative NLR influenced not only long-term outcomes but also perioperative outcomes in gastric cancer patients. Preoperative NLR is also a useful predictive value of short-term outcomes in gastric cancer patients.

The Prognostic Significance of an R1 Resection in Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy

2013 ◽  
Vol 21 (4) ◽  
pp. 1107-1114 ◽  
Author(s):  
Jurriën Stiekema ◽  
Anouk K. Trip ◽  
Edwin P. M. Jansen ◽  
Henk Boot ◽  
Annemieke Cats ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Adjuvant Chemoradiotherapy ◽  
R1 Resection ◽  
Gastric Cancer Patients

scholarly journals Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy

2012 ◽  
Vol 16 (2) ◽  
pp. 233-238 ◽  
Author(s):  
Alexandre A. A. Jácome ◽  
Durval R. Wohnrath ◽  
Cristovam Scapulatempo Neto ◽  
José Humberto T. G. Fregnani ◽  
Ana Luiza Quinto ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Adjuvant Chemoradiotherapy ◽  
D2 Lymphadenectomy ◽  
Gastric Cancer Patients

scholarly journals EVALUATION OF N-RATIO IN SELECTING PATIENTS FOR ADJUVANT CHEMORADIOTHERAPY AFTER D2-GASTRECTOMY

2013 ◽  
Vol 50 (4) ◽  
pp. 257-263 ◽  
Author(s):  
Wilson Luiz da COSTA JUNIOR ◽  
Felipe José Fernández COIMBRA ◽  
Thales Paulo BATISTA ◽  
Héber Salvador de Castro RIBEIRO ◽  
Alessandro Landskron DINIZ
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Continuous Variable ◽  
Lymphatic Spread ◽  
Adjuvant Chemoradiotherapy ◽  
D2 Gastrectomy ◽  
C Statistic ◽  
Cox's Regression ◽  
Area Under Roc Curve ◽  
Gastric Cancer Patients

ContextWhether adjuvant chemoradiotherapy may contribute to improve survival outcomes after D2-gastrectomy remains controvertial.ObjectiveTo explore the clinical utility of N-Ratio in selecting gastric cancer patients for adjuvant chemoradiotherapy after D2-gastrectomy.MethodsA retrospective cohort study was carried out on gastric cancer patients who underwent D2-gastrectomy alone or D2-gastrectomy plus adjuvant chemoradiotherapy (INT-0116 protocol) at the Hospital A. C. Camargo from September 1998 to December 2008. Statistical analysis were performed using multiple conventional methods, such as c-statistic, adjusted Cox's regression and stratified survival analysis.ResultsOur analysis involved 128 patients. According to c-statistic, the N-Ratio (i.e., as a continuous variable) presented “area under ROC curve” (AUC) of 0.713, while the number of metastatic nodes presented AUC of 0.705. After categorization, the cut-offs provide by Marchet et al. displayed the highest discriminating power – AUC value of 0.702. This N-Ratio categorization was confirmed as an independent predictor of survival using multivariate analyses. There also was a trend of better survival by adding of adjuvant chemoradiotherapy only for patients with milder degrees of lymphatic spread – 5-year survival of 23.1% vs 66.9%, respectively (HR = 0.426, 95% CI 0.150–1.202; P = 0.092).ConclusionsThis study confirms the N-Ratio as a tool to improve the lymph node metastasis staging in gastric cancer and suggests the cut-offs provided by Marchet et al. as the best way for its categorization after a D2-gastrectomy. In these settings, the N-Ratio appears a useful tool to select patients for adjuvant chemoradiotherapy, and the benefit of adding this type of adjuvancy to D2-gastrectomy is suggested to be limited to patients with milder degrees of lymphatic spread (i.e., NR2, 10%–25%).

Sign in / Sign up

Export Citation Format

Share Document